Rekha John, MD
Nephrology · Kinston, NCNPI 1619979846
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (52.2%), food and beverage and education — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by CSL Behring at 58.7% of the total. Reporting peaked in 2024 at $2,789 and has fallen 86.1% since, to $389 in 2025.
Across 79 payments — averaging $54.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$3K
- AstraZeneca$570
- Otsuka America Pharmaceutical, Inc.$161
- Vifor Pharma, Inc.$116
- Novartis$116
- Calliditas Therapeutics US Inc.$103
- plus $716 from 14 others
Across 1,040 payments — averaging $2251.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$859K
- Akebia Therapeutics Inc$652K
- Vertex$405K
- Bayer$167K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$127K
- Ardelyx, Inc.$86K
- plus $44K from 3 others
What the payments were for
- Travel & lodging$2,25452%
- Food & beverage$2,05948%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 11 | $2,537 |
| AstraZeneca(2 entities) | 15 | $570 |
| Otsuka America Pharmaceutical, Inc. | 4 | $161 |
| Vifor Pharma, Inc. | 7 | $116 |
| Novartis | 4 | $116 |
| Calliditas Therapeutics US Inc. | 4 | $103 |
| Amgen(2 entities) | 5 | $102 |
| Corvista Health, Inc. | 1 | $94 |
| Fresenius USA Marketing, Inc. | 4 | $70 |
| GSK | 2 | $66 |
| Akebia Therapeutics Inc | 3 | $63 |
| Shield Therapeutics Inc | 3 | $59 |
| Bayer | 3 | $51 |
| Travere Therapeutics, Inc. | 4 | $42 |
| Boehringer Ingelheim | 2 | $42 |
| Mallinckrodt Hospital Products Inc. | 2 | $29 |
| Aurinia Pharma U.S., Inc. | 2 | $28 |
| Novo Nordisk | 1 | $26 |
| Sanofi | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,319 in reported general payments places this provider in the 75th percentile of 366 nephrology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 106 | $64,961 |
| AuryxiaFerric Citrate | 11 | $28,827 |
| JardianceEmpagliflozin | 34 | $19,692 |
| VeltassaPatiromer Calcium Sorbitex | 19 | $10,355 |
| Sevelamer Carbonate | 53 | $6,823 |
| Clonidine | 31 | $2,791 |
| Calcium Acetate | 36 | $1,694 |
| Calcitriol | 142 | $1,542 |
| Nifedipine ErNifedipine | 27 | $1,256 |
| Losartan Potassium | 119 | $796 |
| Bumetanide | 31 | $714 |
| Atorvastatin Calcium | 24 | $602 |
| Potassium Chloride | 41 | $593 |
| Lisinopril | 82 | $363 |
| Metoprolol Succinate | 24 | $335 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $570 | $64,961106 claims |
| Akebia Therapeutics IncAuryxia | $63 | $28,82711 claims |
| Boehringer IngelheimJardiance | $42 | $19,69234 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 366 nephrology providers in North Carolina.
Other nephrology in Kinston
- Gregory GreenwoodWinston-Salem$947K
- Michael EtomiCharlotte$212K
- William KendrickGreenville$125K
- Jason EckelCary$123K
- Raven VooraSanford$111K
- Nam VoAsheville$89K
- Jennifer StoddardPinehurst$77K
- Barry FreedmanWinston Salem$67K
- James McCabeWilmington$56K
- Sammy MoghaziRaleigh$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.